Oregon Dropped Its Psilocybin Fee Hike After Licensees Said They Would Walk
Oregon just dropped a plan to double licensing fees on its psilocybin industry. The reason is worth more than the news itself. Operators surveyed their own people. Enough said they would not renew that the higher fees looked likely to raise less money than the current ones. The Lund Report covered the reversal.
Fees are one line on a license. Everything else is overhead you can negotiate. HealingMaps’ GPO, the first built for the ketamine industry, gets member clinics 40 percent or more off medical supplies, 15 to 20 percent off malpractice and liability premiums, discounted LegitScript certification, and 20 to 30 percent off HIPAA compliant payment processing. Joining is free with no obligation. See what your clinic qualifies for →
| Key Takeaway | Detail |
|---|---|
| What was proposed | Manufacturer and therapy center licenses doubling to $20,000 a year |
| Who else | Facilitators paying $2,000 more a year, new labs doubling to $20,000 from 2029 |
| Also cut | Reduced fee eligibility for some providers would have ended |
| What happened | Oregon Health Authority dropped the proposal on September 29 |
| Why it matters | The program is funded entirely by its own licensee fees |
| The lesson | A fee increase can lower revenue if enough licensees walk |
What Oregon Proposed
The Oregon Health Authority floated the new fee schedule in June, aiming at the program’s costs for next year. Annual licenses for manufacturers and therapy centers would have doubled to $20,000.
Session facilitators would have paid $2,000 more each year. New laboratories would have seen fees double to $20,000 starting in 2029.
The proposal also removed reduced fee eligibility for some providers. That piece drew the sharpest objections, because it hit the smallest operators hardest.
The Argument That Won
Heidi Pendergast, Oregon director at Healing Advocacy, pointed to survey work from inside the community. It asked whether licensees would renew at doubled rates.
Her summary was blunt. A lot of people would not renew. That could bring the state less money than the current fee level does.
That is a revenue argument, not a fairness argument. It is the one a budget office has to answer. Pendergast also warned the increase would push prices up for patients, in a program whose clients already skew wealthy.
Why a Fee Spiral Is a Real Risk
Oregon regulates its psilocybin program using money the program itself generates. No general fund support carries it.
That design has a trap. When licensee numbers fall, the cost per remaining licensee has to rise, which can push more licensees out.
Safety oversight costs money regardless. We covered Oregon’s own adverse event data in our look at how the state tracks safety. That monitoring exists because someone funds it.
What the OHA Actually Did
On September 29 the agency said it would not move forward with the fee changes. It cited feedback from public comment, the Oregon Psilocybin Advisory Board and its rule advisory committees.
The agency said it will start a separate rulemaking process on other policies. The underlying funding problem was not solved, only postponed.
Sam Chapman of the Center for Psychedelic Policy said the industry needs to work with the legislature on financial sustainability. He argued some current rules were written expecting the therapy to be less safe than it has proven.
What This Means for Clinics Outside Oregon
A clinician weighing a psilocybin license elsewhere should read this as a cost forecast. It is not just a local dispute. Oregon is the oldest program and the clearest data set.
New Mexico is building a program now, and we covered what its permits do and do not cover. Virginia is waiting on federal approval before its trigger law takes effect.
States that fund oversight entirely through licensees will face this same arithmetic. A federal report has already told states to prepare, as we covered in our piece on that guidance.
The other half of the math is chair time. Fees are annual and fixed. Revenue depends on how many sessions a room can hold, so session length economics decide whether a license pays for itself.
The Bottom Line
The interesting part of this story is not that a state backed down. It is that the industry made a revenue case and the regulator accepted it.
Over 20,000 people have used the Oregon program since 2023. Keeping it funded without pricing out the providers who deliver it is now a legislative question.
Patients looking for supervised care can start with our directory of verified ketamine clinics.
This article is for informational purposes and is not legal or financial advice. Psilocybin services are legal only within state regulated programs.
